Skip to main content
Erschienen in:

01.06.2007 | Leitthema

Hochdosistherapie bei malignen Lymphomen

Eine Standortbestimmung

verfasst von: Prof. Dr. N. Schmitz, M. Nickelsen, A. Sureda

Erschienen in: Die Onkologie | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Hochdosistherapie (HDT) und autologe Transplantation von Blut bildenden Stammzellen sind wichtig in der Behandlung von Lymphompatienten. Daten der European Group for Blood and Marrow Transplantation (EBMT) belegen eine steigende Häufigkeit sowohl von autologen als auch von allogenen Transplantationen bei den meisten Untergruppen der Lymphome. In Anbetracht der neuen Entwicklungen der herkömmlichen Therapie, insbesondere der immer häufigeren Anwendung des monoklonen Anti-CD20-Antikörpers Rituximab sowie des Einsatzes dosisreduzierter Konditionierung vor allogener Transplantation, ist eine Neuabschätzung von HDT und Stammzellentransplantation indiziert, damit die Rolle dieser Modalität im Jahr 2006 neu definiert werden kann.
Literatur
1.
Zurück zum Zitat Alvarez I, Sureda A, Caballero MD et al. (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 12: 172–183PubMedCrossRef Alvarez I, Sureda A, Caballero MD et al. (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol. Biol Blood Marrow Transplant 12: 172–183PubMedCrossRef
2.
Zurück zum Zitat Betticher D, von Rohr A, Kovacsovics T et al. (2005) Sequential high-dose chemotherapy (SHDC) with autologous stem cell transplantation (ASCT) vs standard CHOP regimen for pts with untreated aggressive NHL. Result of the mistral trial from the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16: 100–101 Betticher D, von Rohr A, Kovacsovics T et al. (2005) Sequential high-dose chemotherapy (SHDC) with autologous stem cell transplantation (ASCT) vs standard CHOP regimen for pts with untreated aggressive NHL. Result of the mistral trial from the Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 16: 100–101
3.
Zurück zum Zitat Brugger W, Hirsch J, Grunebach F et al. (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15: 1691–1698PubMedCrossRef Brugger W, Hirsch J, Grunebach F et al. (2004) Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 15: 1691–1698PubMedCrossRef
4.
Zurück zum Zitat Coiffier B, Lepage E, Briere J et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–242PubMedCrossRef Coiffier B, Lepage E, Briere J et al. (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346: 235–242PubMedCrossRef
5.
Zurück zum Zitat Deconinck E, Foussard C, Milpied N et al. (2005) High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS. Blood 105: 3817–3823PubMedCrossRef Deconinck E, Foussard C, Milpied N et al. (2005) High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS. Blood 105: 3817–3823PubMedCrossRef
6.
Zurück zum Zitat Diehl V, Franklin J, Pfreundschuh M et al. (2003) Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin’s Disease. N Engl J Med 348: 2386–2395PubMedCrossRef Diehl V, Franklin J, Pfreundschuh M et al. (2003) Standard and Increased-Dose BEACOPP Chemotherapy Compared with COPP-ABVD for Advanced Hodgkin’s Disease. N Engl J Med 348: 2386–2395PubMedCrossRef
7.
Zurück zum Zitat Dreyling M, Lenz G, Hoster E et al. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105: 2677–2684PubMedCrossRef Dreyling M, Lenz G, Hoster E et al. (2005) Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 105: 2677–2684PubMedCrossRef
8.
Zurück zum Zitat Federico M, Bellei M, Brice P et al. (2003) High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin’s Lymphoma Responding to Front-Line Therapy. J Clin Oncol 21: 2320–2325PubMedCrossRef Federico M, Bellei M, Brice P et al. (2003) High-Dose Therapy and Autologous Stem-Cell Transplantation Versus Conventional Therapy for Patients With Advanced Hodgkin’s Lymphoma Responding to Front-Line Therapy. J Clin Oncol 21: 2320–2325PubMedCrossRef
9.
Zurück zum Zitat Gianni AM, Bregni M, Siena S et al. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290–1297PubMedCrossRef Gianni AM, Bregni M, Siena S et al. (1997) High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 336: 1290–1297PubMedCrossRef
10.
Zurück zum Zitat Gisselbrecht C, Lepage E, Molina T et al. (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20: 2472–2479PubMedCrossRef Gisselbrecht C, Lepage E, Molina T et al. (2002) Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 20: 2472–2479PubMedCrossRef
11.
Zurück zum Zitat Glass B, Kloess M, Reiser M et al. (2006) Repetitive high-dose therapy followed by autologous stem cell trasplantation (MegaCHOEP) for primary treatment of aggressive NHL: the impact of rituximab on outcome and toxicity. Bone Marrow Transplant 37 [Suppl 1]: O239 Glass B, Kloess M, Reiser M et al. (2006) Repetitive high-dose therapy followed by autologous stem cell trasplantation (MegaCHOEP) for primary treatment of aggressive NHL: the impact of rituximab on outcome and toxicity. Bone Marrow Transplant 37 [Suppl 1]: O239
12.
Zurück zum Zitat Haioun C, Lepage E, Gisselbrecht C et al. (2000) Survival benefit of high-dose therapy in poor risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol – a groupe d’Etude des lymphomes de I’Adulte study. J Clin Oncol 18: 3025–3030PubMed Haioun C, Lepage E, Gisselbrecht C et al. (2000) Survival benefit of high-dose therapy in poor risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87–2 protocol – a groupe d’Etude des lymphomes de I’Adulte study. J Clin Oncol 18: 3025–3030PubMed
13.
Zurück zum Zitat Hiddemann W, Kneba M, Dreyling M et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725–3732PubMedCrossRef Hiddemann W, Kneba M, Dreyling M et al. (2005) Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106: 3725–3732PubMedCrossRef
14.
Zurück zum Zitat Hunault-Berger M, Ifrah N, Solal-Celigny P, for the Group Quest-Est des Leucémies Aiguës et des Maladies du Sang (GOELAMS) (2002) Intensive therapies in follicular non-Hodgkin lymphomas. Blood 100: 1141–1152PubMed Hunault-Berger M, Ifrah N, Solal-Celigny P, for the Group Quest-Est des Leucémies Aiguës et des Maladies du Sang (GOELAMS) (2002) Intensive therapies in follicular non-Hodgkin lymphomas. Blood 100: 1141–1152PubMed
15.
Zurück zum Zitat Kaiser U, Uebelacker I, Abel U et al. (2002) Randomized study to evaluate the use of high-dose therapy as part of primary treatment for „aggressive“ lymphoma. J Clin Oncol 20: 4413–4419PubMedCrossRef Kaiser U, Uebelacker I, Abel U et al. (2002) Randomized study to evaluate the use of high-dose therapy as part of primary treatment for „aggressive“ lymphoma. J Clin Oncol 20: 4413–4419PubMedCrossRef
16.
Zurück zum Zitat Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. (2001) Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 93: 22–30PubMedCrossRef Kluin-Nelemans HC, Zagonel V, Anastasopoulou A et al. (2001) Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin’s lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 93: 22–30PubMedCrossRef
17.
Zurück zum Zitat Lenz G, Dreyling M, Schiegnitz E et al. (2004) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 22: 4926–4933PubMedCrossRef Lenz G, Dreyling M, Schiegnitz E et al. (2004) Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group. J Clin Oncol 22: 4926–4933PubMedCrossRef
18.
Zurück zum Zitat Linch DC, Winfield D, Goldstone AH et al. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341: 1051–1054PubMedCrossRef Linch DC, Winfield D, Goldstone AH et al. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of a BNLI randomised trial. Lancet 341: 1051–1054PubMedCrossRef
19.
Zurück zum Zitat Martelli M, Gherlinzoni F, De Renzo A et al. (2003) Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian multicenter randomized trial. J Clin Oncol 21: 1255–1262PubMedCrossRef Martelli M, Gherlinzoni F, De Renzo A et al. (2003) Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin’s lymphoma: an Italian multicenter randomized trial. J Clin Oncol 21: 1255–1262PubMedCrossRef
20.
Zurück zum Zitat Milpied N, Deconinck E, Gaillard F et al. (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350: 1287–1295PubMedCrossRef Milpied N, Deconinck E, Gaillard F et al. (2004) Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 350: 1287–1295PubMedCrossRef
21.
Zurück zum Zitat Peggs KS, Hunter A, Chopra R et al. (2005) Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365: 1934–1941PubMedCrossRef Peggs KS, Hunter A, Chopra R et al. (2005) Clinical evidence of a graft-versus-Hodgkin’s-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365: 1934–1941PubMedCrossRef
22.
Zurück zum Zitat Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31: 667–678PubMedCrossRef Peniket AJ, Ruiz de Elvira MC, Taghipour G et al. (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant 31: 667–678PubMedCrossRef
23.
Zurück zum Zitat Perez-Simon JA, Kottaridis PD, Martino R et al. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100: 3121–3127PubMedCrossRef Perez-Simon JA, Kottaridis PD, Martino R et al. (2002) Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders. Blood 100: 3121–3127PubMedCrossRef
24.
Zurück zum Zitat Pfreundschuh M, Truemper L, Oesterborg A et al. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol 379–391 Pfreundschuh M, Truemper L, Oesterborg A et al. (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MinT) Group. Lancet Oncol 379–391
25.
Zurück zum Zitat Philip T, Guglielmi C, Hagenbeek A et al. (1995) Autologous Bone Marrow Transplantation As Compared With Salvage Chemotherapy In Relapses Of Chemotherapy-Sensitive Non-Hodgkin’s Lymphoma. N Engl J Med 333: 1540–1545PubMedCrossRef Philip T, Guglielmi C, Hagenbeek A et al. (1995) Autologous Bone Marrow Transplantation As Compared With Salvage Chemotherapy In Relapses Of Chemotherapy-Sensitive Non-Hodgkin’s Lymphoma. N Engl J Med 333: 1540–1545PubMedCrossRef
26.
Zurück zum Zitat Robinson SP, Goldstone AH, Mackinnon S et al. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100: 4310–4316PubMedCrossRef Robinson SP, Goldstone AH, Mackinnon S et al. (2002) Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 100: 4310–4316PubMedCrossRef
27.
Zurück zum Zitat Schmitz N, Haverkamp H, Josting A et al. (2005) Long term follow up in relapsed Hodgkin’s disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Proc ASCO 23: 562 s Schmitz N, Haverkamp H, Josting A et al. (2005) Long term follow up in relapsed Hodgkin’s disease (HD): Updated results of the HD-R1 study comparing conventional chemotherapy (cCT) to high-dose chemotherapy (HDCT) with autologous haemopoietic stem cell transplantation (ASCT) of the German Hodgkin Study Group (GHSG) and the Working Party Lymphoma of the European Group for Blood and Marrow Transplantation (EBMT). Proc ASCO 23: 562 s
28.
Zurück zum Zitat Schmitz N, Pfistner B, Sextro M et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359: 2065–2071PubMedCrossRef Schmitz N, Pfistner B, Sextro M et al. (2002) Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haematopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet 359: 2065–2071PubMedCrossRef
29.
Zurück zum Zitat Schouten HC, Qian W, Kvaloy S et al. (2003) High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From The Randomized European CUP Trial. J Clin Oncol 21: 3918–3927PubMedCrossRef Schouten HC, Qian W, Kvaloy S et al. (2003) High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From The Randomized European CUP Trial. J Clin Oncol 21: 3918–3927PubMedCrossRef
30.
Zurück zum Zitat Sebban C, Belanger C, Brousse N et al. (2003) Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 Trial (G.E.L.A. Study Group). Blood 102: 354a Sebban C, Belanger C, Brousse N et al. (2003) Comparison of CHVP + interferon with CHOP followed by autologous stem cell transplantation with a TBI conditioning regimen in untreated patients with high tumor burden follicular lymphoma: results of the randomized GELF94 Trial (G.E.L.A. Study Group). Blood 102: 354a
31.
Zurück zum Zitat Sureda A, Robinson S, Ruiz de Elvira C et al. (2003) Non myeloablative allogeneic stem cell transplantation reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed or refractory Hodgkin’s Disease: Results of the European group for Blood and Marrow Transplantation. Blood 102 [Suppl 1]: 198a Sureda A, Robinson S, Ruiz de Elvira C et al. (2003) Non myeloablative allogeneic stem cell transplantation reduces transplant related mortality in comparison with conventional allogeneic transplantation in relapsed or refractory Hodgkin’s Disease: Results of the European group for Blood and Marrow Transplantation. Blood 102 [Suppl 1]: 198a
32.
Zurück zum Zitat Verdonck LF, van Putten WL, Hagenbeek A et al. (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 332: 1045–1051PubMedCrossRef Verdonck LF, van Putten WL, Hagenbeek A et al. (1995) Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 332: 1045–1051PubMedCrossRef
33.
Zurück zum Zitat Zanni M, Di Nicola M, Patti C et al. (2004) Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis. Blood 104 [Suppl 1]: 891 Zanni M, Di Nicola M, Patti C et al. (2004) Rituximab-Supplemented High-Dose Sequential (HDS) Chemotherapy with Autograft Is Highly Effective in High-Risk (aaIPI 2–3) Diffuse Large B-Cell Lymphoma: Results of a Prospective Multicenter Study on 91 Consecutive Patients Treated at Diagnosis. Blood 104 [Suppl 1]: 891
Metadaten
Titel
Hochdosistherapie bei malignen Lymphomen
Eine Standortbestimmung
verfasst von
Prof. Dr. N. Schmitz
M. Nickelsen
A. Sureda
Publikationsdatum
01.06.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 5/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-006-1118-3

Weitere Artikel der Ausgabe 5/2007

Der Onkologe 5/2007 Zur Ausgabe

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.